CANADIAN CANCER TRIALS GROUP – GI DISEASE SITE COMMITTEE

RECTAL
DISEASE ORIENTED GROUP

AGENDA
OPEN SESSION

VENUE: ROSSETTI ROOM, CHELSEA HOTEL, TORONTO
DATE: SATURDAY, APRIL 30th, 2016
TIME: 09:15 – 10:00
CHAIRS: DR. HAGEN KENNECKE & DR. REBECCA AUER

09:15 WELCOME AND INTRODUCTION
DR. H. KENNECKE / DR. R. AUER

09:20 ACTIVE TRIALS FOR UPDATE/DISCUSSION

**CRC.7 (NCCTG N1048- PROSPECT):** A PHASE II/III TRIAL OF NEOADJUVANT FOLFOX, WITH SELECTIVE USE OF COMBINED MODALITY CHEMORADIATION VERSUS PREOPERATIVE COMBINED MODALITY CHEMORADIATION FOR LOCALLY ADVANCED RECTAL CANCER PATIENTS UNDERGOING LOW ANTERIOR RESECTION WITH TOTAL MESORECTAL EXCISION
DR. H. KENNECKE

09:25 APPROVED TRIALS IN DEVELOPMENT

**CO.28:** PHASE II: NON-OPERATIVE MANAGEMENT OF CT1-3 N0 LOW RECTAL CANCER
DR. C. BROWN/DR. H. KENNECKE

09:40 TRIAL CONCEPTS IN DEVELOPMENT

A SINGLE ARM PHASE II STUDY OF DURVALUMAB AND TREMELIMUMAB IN PATIENTS WITH ADVANCED SQUAMOUS CELL CARCINOMA OF THE ANAL CANAL
DR. E. CHEN

**CREATE:** CHEMOTHERAPY FOR RECTAL CANCER BEFORE OR AFTER LOCAL TREATMENT
DR. H. KENNECKE

09:55 INTERGROUP TASK FORCE UPDATE

**TNT (NRG GI-002):** A PHASE II CLINICAL TRIAL PLATFORM OF SENSITIZATION UTILIZING TOTAL NEOADJUVANT THERAPY (TNT) IN RECTAL CANCER
DR. H. KENNECKE

10:00 CLOSING REMARKS